Thymus-related Myasthenia Gravis. Multimodal Therapy and Follow-up

  • Riccarda Gentile
  • Loredana Capone
  • Rudolf Schoenhuber


Over the last 30 years Myasthenia Gravis (MG) has become amenable to successful treatment, primarily from the remarkable advances in our understanding of the biology of neuromuscular transmission and of pathogenic processes underlying the disorder [1, 2, 3, 4, 5]. With treatment, today, most patients can expect to lead normal or nearly normal lives. Some cases of MG may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued.


Plasma Exchange Neuromuscular Junction Intravenous Immunoglobulin Mycophenolate Mofetil Multimodal Therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141–149PubMedCrossRefGoogle Scholar
  2. 2.
    Conti-Fine BM, Milani M, Kaminsk HJ (2006) Myasthenia gravis: Past, present, and future. J Clin Invest 116:2843–2854PubMedCrossRefGoogle Scholar
  3. 3.
    Hirsch NP (2007) Neuromuscular junction in health and disease. Br J Anaesth 99:132–138PubMedCrossRefGoogle Scholar
  4. 4.
    Mahadeva B, Phillips LH, Juel VC (2008) Autoimmune disorders of neuromuscular transmission. Semin Neurol 28:212–227PubMedCrossRefGoogle Scholar
  5. 5.
    Juel VC, Massey JM (2007) Myasthenia gravis. Orphannet J Rare Dis 2:44CrossRefGoogle Scholar
  6. 6.
    Keesey JC (2004) A history of treatments for myasthenia gravis. Semin Neurol 24:5–16PubMedCrossRefGoogle Scholar
  7. 7.
    Pascuzzi RM (1994) The history of myasthenia gravis. Neurol Clin 12:231–242PubMedGoogle Scholar
  8. 8.
    Hughes T (2005) The early history of myasthenia gravis. Neuromuscul Disord 15:878–886PubMedCrossRefGoogle Scholar
  9. 9.
    Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: Recommendations for clinical research standards. Ann Thorac Surg 70:327–334PubMedCrossRefGoogle Scholar
  10. 10.
    Benatar M (2006) A systematic review of diagnostic studies in myasthenia gravis. Neuromusc Dis 16:459–467PubMedCrossRefGoogle Scholar
  11. 11.
    Richman DP, Agius MA (2003) Treatment principles in the management of autoimmune Myasthenia Gravis. Ann NY Acad Sci 998:457–472PubMedCrossRefGoogle Scholar
  12. 12.
    Hilton-Jones D, Palace J (2005) The management of myasthenia gravis. Pract Neurol 5:18–27CrossRefGoogle Scholar
  13. 13.
    Skeie GO, Aposolski S, Evoli A et al (2006) Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neur 13:691–699CrossRefGoogle Scholar
  14. 14.
    Hilton-Jones D (2007) When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol 7:405–411PubMedCrossRefGoogle Scholar
  15. 15.
    National Institute of Neurological Disorders and Stroke., Scholar
  16. 16.
    Mendiratta MM, Kuntzer T, Pandey S (2008) Anticholinesterase treatment for myasthenia gravis (Protocol). Cochrane Databases of Systematic Reviews, Issue 1Google Scholar
  17. 17.
    Schneider-Gold C, Gajdos P, Tojka KV, Hohlfeld RR (2005) Corticosteroids for myasthenia gravis. Cochrane Databases of Systematic Reviews, Issue 2Google Scholar
  18. 18.
    Gajdos P, Chevret S, Toyka K (2002) Plasma exchange for myasthenia gravis (review). Cochrane Databases of Systematic Reviews, Issue 1Google Scholar
  19. 19.
    Gajdos P, Tranchant C, Clair B et al (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin. A randomized double-blind clinical trial. Arch Neurol 62:1689–1693PubMedCrossRefGoogle Scholar
  20. 20.
    Gajdos P, Chevret S, Toyka K (2006) Intravenous immunoglobulin for myasthenia gravis (review). Cochrane Databases of Systematic Reviews, Issue 1Google Scholar
  21. 21.
    Gronseth GS, Barohn RJ (2000) Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence based review). Neurology 55:7–15PubMedGoogle Scholar
  22. 22.
    Shahrizaila N, Pacheco OA, Vidal DG et al (2005) Thymectomy in myasthenia gravis: Comparison of outcome in Santiago, Cuba and Nottingham, UK. J Neurol 252:1262–1266PubMedCrossRefGoogle Scholar
  23. 23.
    Hart IK, Sathasivam S, Sharshar T (2007) Immunosuppresive agents for myasthenia gravis. Cochrane Databases of Systematic Reviews, Issue 4Google Scholar
  24. 24.
    Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB (2001) Mycophenolate mofetil for myasthenia gravis: An open-label pilot study. Neurology 56:97–99PubMedGoogle Scholar
  25. 25.
    Meriggioli MN, Ciafaloni E, Al-Hayk KA et al (2003) Mycophenolate mofetil for myasthenia gravis. An analysis of efficacy, safety and tolerability. Neurology 61:1438–1440PubMedGoogle Scholar
  26. 26.
    Kakoulidou M, Bjelak S, Pirskanen R, Lefvert AK (2007) A clinical and immunological study of myasthenia gravis treated with infliximab. Acta Neurol Scand 115:279–283PubMedCrossRefGoogle Scholar
  27. 27.
    Hoff JM, Daltveit AK, Gilhus NE (2007) Myasthenia gravis in pregnancy and birth: Identifying risk factors, optimising care. Eur J Neurol 14:38–43PubMedCrossRefGoogle Scholar
  28. 28.
    Agius MA (2000) Treatment of ocular myasthenia with corticosteroids. Arch Neurol 57:750–751PubMedCrossRefGoogle Scholar
  29. 29.
    Kaminski HJ, Daroff R (2000) Treatment of ocular myasthenia. Steroid only when compelled. Arch Neurol 57:752–753PubMedCrossRefGoogle Scholar
  30. 30.
    Benatar M, Kaminski H (2006) Medical and surgical treatment for ocular myasthenia. Cochrane Databases of Systematic Reviews, Issue 1Google Scholar
  31. 31.
    Benatar M, Kaminski HJ (2007) Evidence report: The medical treatment of ocular myasthenia (an evidencebased review). Neurology 68:2144–2149PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  • Riccarda Gentile
    • 1
  • Loredana Capone
    • 1
  • Rudolf Schoenhuber
    • 1
  1. 1.Department of NeurologyBolzano HospitalBolzanoItaly

Personalised recommendations